Advanced search
Publication Cover
HIV Clinical Trials Volume 14, 2013 - Issue 4
Submit an article Journal homepage
65
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Baseline CD4+ T-Cell Counts Predict HBV Viral Kinetics to Adefovir Treatment in Lamivudine-Resistant HBV-Infected Patients with or without HIV Infection

K. J. CortezDivision of Human TissuesOffice of Cell Therapy and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA
,
M. A. ProschanBiostatistics Research BranchNational Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA
,
L. BarrettLaboratory of ImmunoregulationNIAID, National Institutes of Health (NIH), Bethesda, Maryland, USA
,
D. G. BrustDivision of Infectious DiseasesLee Memorial Health System, Fort Myers, Florida, USA
,
E. FormentiniDivision of Microbiology and Infectious DiseasesNIH, Bethesda, Maryland, USA
,
R. T. DaveyLaboratory of ImmunoregulationNIAID, National Institutes of Health (NIH), Bethesda, Maryland, USA
,
H. MasurCritical Care Medicine DepartmentClinical Center, NIH, Department of Health and Human Services, Bethesda, Maryland, USA
,
M. A. PolisLaboratory of ImmunoregulationNIAID, National Institutes of Health (NIH), Bethesda, Maryland, USA
,
A. U. Neumann, andBar-Ilan UniversityRamat Dan, Israel
&
S. KottililLaboratory of ImmunoregulationNIAID, National Institutes of Health (NIH), Bethesda, Maryland, USACorrespondence[email protected]
 show all
Pages 149-159 | Published online: 22 Dec 2014

REFERENCES

  • Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res. 2011;188:75–84.
  • Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–1771.
  • Konopnicki D, Mocroft A, de Wit S, et al; EuroSIDA Group. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortal-ity in the EuroSIDA cohort. AIDS. 2005;19:593–601.
  • Soriano V, Puoti M, Peters M, Benhamou Y, et al. Care of HIV patients with chronic hepatitis B: Updated recommen-dations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008,22:1399–1410.
  • Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J HepatoL 1998;29:306–309.
  • Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491–498.
  • Marcellin P, Bonino F, Lau GK, et al; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sus-tained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gas-troenterology. 2009;136:2169–2179.
  • Vela JE, Olson LY, Huang A, Fridland A, Ray AS. Simul-taneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2’-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Scl. 2007;848:335–433.
  • Lau GK, et al. Impact of early viral kinetics on T-cell reac-tivity during antiviral therapy in chronic hepatitis B. Antivir Ther. 2007;12:705–718.
  • Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infec-tion and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169–1179.
  • Ribeiro RM, Germanidis G, Powers KA, et al. Hepatitis B virus kinetics under antiviral therapy sheds light on differ-ences in hepatitis B e antigen positive and negative infec-tions. J Infect Dis. 2010;202:1309–1318.
  • Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002;4:27–35.
  • Mallet VO, Dhalluin-Venier V, Verkarre V, et al. Revers-ibility of cirrhosis in HIV/HBV coinfection. Antivir Ther. 2007;12:279–283.
  • Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol. 2009;3:499–512.
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1—infected adults and adolescents. December 1, 2009. Department of Health and Human Services. http://aidsinfo.nih.gov/guidelines
  • Lewin SR, Ribeiro RM, Avihingsanon A, et al. Viral dynam-ics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology. 2009;49:1113–1121.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.